MX385333B - Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas. - Google Patents

Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas.

Info

Publication number
MX385333B
MX385333B MX2016013332A MX2016013332A MX385333B MX 385333 B MX385333 B MX 385333B MX 2016013332 A MX2016013332 A MX 2016013332A MX 2016013332 A MX2016013332 A MX 2016013332A MX 385333 B MX385333 B MX 385333B
Authority
MX
Mexico
Prior art keywords
vî39vî
human
cell receptors
binding human
immunoglobulins binding
Prior art date
Application number
MX2016013332A
Other languages
English (en)
Other versions
MX2016013332A (es
Inventor
Hendrik Marinus Willem Verheul
Der Vliet Johannes Jelle Van
Bruin Renée Cornelia Gerarda De
Gruijl Tanja Denise De
Original Assignee
Lava Therapeutics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics N V filed Critical Lava Therapeutics N V
Publication of MX2016013332A publication Critical patent/MX2016013332A/es
Publication of MX385333B publication Critical patent/MX385333B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a está en el campo de la medicina y se refiere a la inmunología, y se refiere en particular a moléculas de inmunoglobulina que se unen al receptor de célula T V?9Vd2 humanas; las moléculas de inmunoglobulina que se unen al receptor de célula T V?9Vd2 humanas son en particular para su uso en el tratamiento médico y/o útiles en pruebas con células T V?9Vd2 humanas, en donde la células T V?9Vd2 humanas pueden ser moduladas.
MX2016013332A 2014-04-10 2015-04-10 Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas. MX385333B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2012604 2014-04-10
PCT/NL2015/050235 WO2015156673A1 (en) 2014-04-10 2015-04-10 IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Publications (2)

Publication Number Publication Date
MX2016013332A MX2016013332A (es) 2017-05-01
MX385333B true MX385333B (es) 2025-03-18

Family

ID=50896416

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013332A MX385333B (es) 2014-04-10 2015-04-10 Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas.
MX2021009674A MX2021009674A (es) 2014-04-10 2016-10-10 Receptores de celulas t vgamma9vdelta2 humanas que se unen a inmunoglobulinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009674A MX2021009674A (es) 2014-04-10 2016-10-10 Receptores de celulas t vgamma9vdelta2 humanas que se unen a inmunoglobulinas.

Country Status (10)

Country Link
US (4) US10501540B2 (es)
EP (1) EP3129404A1 (es)
JP (4) JP6617138B2 (es)
KR (2) KR102359264B1 (es)
CN (2) CN106536557B (es)
AU (3) AU2015244489B2 (es)
EA (2) EA039086B1 (es)
MX (2) MX385333B (es)
SG (2) SG11201609417VA (es)
WO (1) WO2015156673A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3220926T3 (da) * 2014-11-17 2025-03-24 Adicet Therapeutics Inc Konstruerede gamma-delta-t-celler
JP6743051B2 (ja) 2015-01-27 2020-08-19 ラヴァ・セラピューティクス・ベー・フェー Ｃｄ１ｄを標的とする単一ドメイン抗体
WO2017197347A1 (en) 2016-05-12 2017-11-16 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
US10356636B2 (en) * 2017-04-03 2019-07-16 Qualcomm Incorporated Techniques and apparatuses to improve drone-mounted user equipment performance
WO2019099744A1 (en) 2017-11-15 2019-05-23 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
CN108659130B (zh) * 2018-05-28 2021-09-10 长春力太生物技术有限公司 一种抗癌胚抗原纳米抗体及其应用
CN112703201A (zh) * 2018-07-05 2021-04-23 诺沃班德畜牧业治疗公司 针对家禽致病原的抗体和其用途
US20220111043A1 (en) * 2018-09-19 2022-04-14 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
SG11202106895UA (en) 2019-01-07 2021-07-29 Shattuck Labs Inc Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
JP2022519082A (ja) 2019-02-01 2022-03-18 ラヴァ・セラピューティクス・ベー・フェー 新規ｃｄ４０結合抗体
JP7308477B2 (ja) * 2019-03-11 2023-07-14 パナソニックＩｐマネジメント株式会社 抗体、複合体、それを用いた検出装置及び検出方法
JP7686571B2 (ja) * 2019-05-08 2025-06-02 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞媒介性免疫を調節するための材料及び方法
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
GB201918279D0 (en) * 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
KR20220147631A (ko) * 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
CA3172449A1 (en) 2020-03-27 2021-09-30 Erik Hans MANTING Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN116133679A (zh) 2020-06-30 2023-05-16 门德斯有限公司 白血病衍生细胞在卵巢癌疫苗中的用途
JP2023532807A (ja) * 2020-07-08 2023-07-31 ラヴァ・セラピューティクス・エヌ・ヴイ Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
AU2021372463A1 (en) * 2020-10-28 2023-06-22 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity
CA3196677A1 (en) 2020-11-05 2022-05-12 Erik Hans MANTING Use of tumor-independent antigens in immunotherapies
CN116635421A (zh) * 2020-11-06 2023-08-22 安进公司 与cd3结合的多肽构建体
US20240024475A1 (en) * 2020-12-01 2024-01-25 Cure Genetics Co., Ltd Antigen-Binding Protein Targeting CD70 and Use Thereof
EP4259660A1 (en) 2020-12-10 2023-10-18 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors
CA3203705A1 (en) 2021-01-22 2022-07-28 Erik Hans MANTING Methods of tumor vaccination
CA3209454A1 (en) 2021-02-26 2022-09-01 Robertus Cornelis ROOVERS Antibodies that bind cd123 and gamma-delta t cell receptors
JP2024533457A (ja) 2021-09-13 2024-09-12 ヤンセン バイオテツク，インコーポレーテツド がんの治療のためのＣＤ３３×Ｖδ２多重特異性抗体
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
CN119213028A (zh) * 2022-01-05 2024-12-27 印希比生物科学有限公司 结合γδ T细胞的多肽及其用途
CN115043936B (zh) * 2022-03-31 2023-06-27 深圳市人民医院 靶向新冠病毒的纳米抗体及其制备方法和应用
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
CN116178538B (zh) * 2023-01-05 2024-08-02 暨南大学 靶向热休克蛋白70的纳米抗体及其制备方法与应用
WO2024173376A2 (en) * 2023-02-13 2024-08-22 LAVA Therapeutics N.V. Combination therapy comprising multispecific gamma delta tcr antibodies
CN116284405B (zh) * 2023-03-15 2024-03-19 中国科学技术大学 靶向cd150蛋白的纳米抗体及其应用
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
EP4438624A1 (en) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
TW202535947A (zh) 2023-12-08 2025-09-16 美商健生生物科技公司 ＣＤ３３抗體、ＣＤ３３／Ｖδ２多特異性抗體及其用途
CN118496370A (zh) * 2024-06-07 2024-08-16 南方医科大学深圳医院 一种靶向alox5纳米抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) * 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
EP2390270A1 (en) * 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
EP1627231A2 (en) * 2003-05-23 2006-02-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Improvements to gamma delta t cell-mediated therapy
EA010350B1 (ru) * 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
ITRM20070437A1 (it) * 2007-08-10 2009-02-11 Istituto Naz Per Le Malattie I Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi
WO2009131730A2 (en) * 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
CN102154205A (zh) * 2011-01-31 2011-08-17 郑骏年 高纯度、高细胞毒活性的γδT细胞的制备方法
EP2807189B1 (en) * 2012-01-23 2019-03-20 Ablynx N.V. Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
CN103571791B (zh) * 2012-02-10 2015-05-13 深圳市合一康生物科技股份有限公司 一种人γδT细胞的形态学、纯度及免疫表型检测方法
PT2831109T (pt) * 2012-03-28 2018-02-07 Gadeta B V Resumo

Also Published As

Publication number Publication date
EA039086B1 (ru) 2021-12-01
JP7583130B2 (ja) 2024-11-13
CN106536557A (zh) 2017-03-22
JP2017513521A (ja) 2017-06-01
JP7342202B2 (ja) 2023-09-11
AU2020213325B2 (en) 2023-03-30
SG10202007233TA (en) 2020-09-29
US10501540B2 (en) 2019-12-10
AU2015244489B2 (en) 2020-08-27
AU2020213325A1 (en) 2020-08-27
CN113105550A (zh) 2021-07-13
KR102359264B1 (ko) 2022-02-04
JP7094931B2 (ja) 2022-07-04
US20170029506A1 (en) 2017-02-02
WO2015156673A1 (en) 2015-10-15
MX2021009674A (es) 2021-09-08
MX2016013332A (es) 2017-05-01
KR102601469B1 (ko) 2023-11-14
KR20170019343A (ko) 2017-02-21
KR20220021015A (ko) 2022-02-21
JP2023165723A (ja) 2023-11-17
US20230212290A1 (en) 2023-07-06
AU2023204215A1 (en) 2023-07-20
AU2015244489A1 (en) 2016-12-01
US20190263908A1 (en) 2019-08-29
EA202192165A1 (ru) 2021-12-31
JP2020029461A (ja) 2020-02-27
EP3129404A1 (en) 2017-02-15
JP2022136078A (ja) 2022-09-15
JP6617138B2 (ja) 2019-12-11
US20220098301A1 (en) 2022-03-31
CN106536557B (zh) 2021-05-04
US11384145B2 (en) 2022-07-12
SG11201609417VA (en) 2016-12-29
EA201692039A1 (ru) 2017-05-31
CA2948812A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
MX385333B (es) Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas.
IL268554A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SA523442262B1 (ar) أجسام مضادة للارتباط بـ cd3
PH12016501644A1 (en) Binding proteins and methods of use thereof
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
MY210545A (en) Chimeric receptors to flt3 and methods of use thereof
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
HUE043038T2 (hu) Regulator T-sejteket szelektíven aktiváló, módosított IL-2-változatok autoimmun betegségek kezelésére
MX387562B (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
BR112018068678A2 (pt) anticorpos anti-mica
EA201791007A3 (ru) Соединения и их применения для модуляции гемоглобина
ECSP13012462A (es) Inmunoglobulinas con dominio variable dual
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
MX2016010953A (es) Proteinas de fc multimericas.
CL2015003174A1 (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
EP3517544C0 (en) INSULIN ANALOGUE HAVING REDUCED BINDING STRENGTH TO INSULIN RECEPTOR AND USE THEREOF
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
JOP20190101A1 (ar) أنظمة علاج
WO2014187964A3 (en) Novel treatment of metabolic diseases
MY181915A (en) Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
WO2014172653A3 (en) Anti-notch1 antibodies